BL, I'm guessing here, remember that, but I would believe they MUST formally publish results because it's material, investors NEED to know, patients and doctors need hope and information, and it's likely (not certainly) a defined milestone triggering a milestone payment.
At Phase I stage I think one main endpoint is you don't kill the test subject. So, tolerance, toxicity, dosage, harm are the keys to progress to Phase II. I can see Phase II being planned for, eg. locations, recruitment. I can see NO WAY for Phase II to begin without Phase I/Ib done and dusted. Might not even be legal to start the next phase before the previous stage is rigorously studied and reported.
News timelines equate to definitive sp catalysts. These things are notoriously slow, I'd like to see end April results, but I'm not holding my breath. Who knows, maybe earlier.
OV
RGS Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
